Project: Development of a novel microbiota-based therapy for the prevention of type 2 diabetes mellitus.
Acronym | PROMISE (Reference Number: 12091) |
Duration | 01/05/2018 |
Project Topic | PROMISE will deliver an innovative microbiota-based therapy based upon the anaerobic human derived butyrate-producing bacterium Eubacterium hallii, for the reduction of insulin resistance and prevention of type 2 diabetes mellitus (T2DM) in individuals suffering from metabolic syndrome (MetS). Additionally, this project adopts a novel approach aiming to set new standards in performing (pre)clinical studies using a microbial therapy in stratified target groups. |
Network | Eurostars 2 |
Call | Eurostars Cut-Off 8 |
Project partner
Number | Name | Role | Country |
---|---|---|---|
1 | Caelus Pharmaceuticals B.V. | Coordinator | Netherlands |
2 | BaseClear B.V. | Partner | Netherlands |
3 | ProDigest BVBA | Partner | Belgium |
4 | Integrated BioBank of Luxembourg | Partner | Luxembourg |